Is Zenas Biopharma Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Zenas Biopharma Inc (ZBIO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Zenas Biopharma Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Zenas Biopharma Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Zenas Biopharma Inc?

Muslim investors may consider investing in Zenas Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Zenas Biopharma Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Zenas Biopharma Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Zenas Biopharma Inc updated?

The Shariah compliance status of Zenas Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Zenas Biopharma Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Zenas Biopharma Inc?

You can check the latest Shariah compliance status of Zenas Biopharma Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ZBIO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 17, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Zenas Biopharma Inc (ZBIO)

Based on 14 analysts giving stock ratings to Zenas Biopharma Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Zenas Biopharma Inc. Stock Analysis ZBIO

United States Health Care Small Cap Report: 2025 Annual

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company is headquartered in Waltham, Massachusetts and currently employs 167 full-time employees. The company went IPO on 2024-09-13. The firm's lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The firm is developing obexelimab as a potential immunology and inflammation (I&I) franchise for patients in several autoimmune diseases. The first three indications it is pursuing include immunoglobulin G4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS) and systemic lupus erythematosus (SLE). Its other programs include ZB002 (an anti-TNFα monoclonal antibody), ZB004 (a CTLA-4-Ig fusion), and ZB001 and related programs. ZB002 is a recombinant human monoclonal antibody directed at human TNFα.

Key Statistics of Zenas Biopharma Inc (ZBIO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$17.39$18.56

Today's Open

$18.45

Volume

642.86K

P/E Ratio (TTM)

52 Week Range

$8.54$44.60

Market Cap

1.27B

Avg. Volume

484.79K

Dividend Yield

Financial Metrics & Statements of Zenas Biopharma Inc (ZBIO)

FAQ's for Zenas Biopharma Inc (ZBIO)

According to Musaffa’s Shariah screening methodology, Zenas Biopharma Inc (ZBIO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.